# Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf)

> **NCT03441633** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 51690 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** apixaban
- **DRUG:** dabigatran
- **DRUG:** VKA
- **DRUG:** rivaroxaban

## Key facts

- **NCT ID:** NCT03441633
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-18
- **Primary completion:** 2017-03-08
- **Final completion:** 2017-03-08
- **Target enrollment:** 51690 (ACTUAL)
- **Last updated:** 2023-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03441633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03441633, "Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03441633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*